Olmesartan Medoxomil/Hydrochlorothiazide Accord Healthcare (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan Medoxil/Hydrochlorothiazide combines an ARB with a thiazide diuretic to manage high blood pressure and related cardiovascular risk.

• Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient.
• Hypertensive heart disease: reduces cardiac workload and helps prevent progression of left‑ventricular hypertrophy.
• Chronic kidney disease with hypertension: aids in slowing renal function decline by controlling systemic pressure.

• Olmesartan medoxil blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. The combined actions produce additive blood‑pressure‑lowering effects.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Liver function abnormalities
• Blood dyscrasias such as agranulocytosis

Before starting therapy, clinicians should assess patient history and monitor relevant parameters.

• Renal function: evaluate baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: check potassium and sodium levels, especially with concomitant potassium‑sparing agents.
• Pregnancy: avoid use; teratogenic risk is associated with ARBs.
• Elderly patients: initiate at lower dose and monitor for orthostatic hypotension.
• Drug‑induced photosensitivity: advise patients to limit excessive sun exposure.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxil/Hydrochlorothiazide may interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): risk of renal impairment and hyperkalemia.
• Potassium‑rich supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• ACE inhibitors or other ARBs: additive risk of hypotension and renal dysfunction.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.